| 40.21 -0.68 (-1.66%) | 07-30 15:41 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 48.22 | 1-year : | 56.32 |
| Resists | First : | 41.29 | Second : | 48.22 |
| Pivot price | 35.84  |
|||
| Supports | First : | 32.6 | Second : | 27.23 |
| MAs | MA(5) : | 38.67 |
MA(20) : | 35.14 |
| MA(100) : | 29.76 |
MA(250) : | 33.67 |
|
| MACD | MACD : | 2.3 |
Signal : | 1.8 |
| %K %D | K(14,3) : | 94.6  |
D(3) : | 94 |
| RSI | RSI(14): 74.2 |
|||
| 52-week | High : | 43.18 | Low : | 25.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ATRC ] has closed below upper band by 3.9%. Bollinger Bands are 141.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 41.29 - 41.44 | 41.44 - 41.57 |
| Low: | 37.53 - 37.7 | 37.7 - 37.86 |
| Close: | 40.6 - 40.85 | 40.85 - 41.09 |
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
Thu, 30 Jul 2026
Are Options Traders Betting on a Big Move in AtriCure Stock? - TradingView
Tue, 28 Jul 2026
AtriCure, Inc. SEC Filing (Jul 28, 2026) - Stock Titan
Tue, 28 Jul 2026
AtriCure, Inc. (ATRC) Beat Earnings Estimates. Here’s What Could Drive ATRC Stock Next - Yahoo Finance
Tue, 28 Jul 2026
ATRC SWOT Analysis: Strong Revenue Growth and Innovation Highlig - GuruFocus
Mon, 27 Jul 2026
AtriCure’s Profitability Inflection and 2026 Guidance Could Be A Game Changer For AtriCure (ATRC) - simplywall.st
Mon, 27 Jul 2026
AtriCure to Participate at Upcoming Investor Conferences - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 51 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 3.8 (%) |
| Held by Institutions | 102.2 (%) |
| Shares Short | 4,860 (K) |
| Shares Short P.Month | 3,440 (K) |
| EPS | 0.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.71 |
| Profit Margin | 1.8 % |
| Operating Margin | 6.2 % |
| Return on Assets (ttm) | 1.2 % |
| Return on Equity (ttm) | 2.1 % |
| Qtrly Rev. Growth | 12.8 % |
| Gross Profit (p.s.) | 8.58 |
| Sales Per Share | 11.24 |
| EBITDA (p.s.) | 0.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 192.07 |
| PEG Ratio | 10 |
| Price to Book value | 4.15 |
| Price to Sales | 3.58 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|